OptionsHouse

Options Trading News

April 5, 2011  Tue 7:33 AM CT

CBST: SEE CHART GET CHAIN FIND STRATEGIES
Deal to Help Cubist Grow Business

CBSTThe drug maker settled a patent dispute with Teva Pharmaceutical Industries over its Cubicin antibiotic. The agreement delays TEVA's production of the drug as a generic by six months and will make it easier for Cubist to market the drug, its only product. CBST is up 15 percent in the premarket.


SemiLEDs Reports Surprise Loss

The maker of light-emitting diodes reported a loss of $0.03, missing the $0.08 profit forecast. Revenue and guidance also missed the mark, and LEDS is down 23 percent before the bell.


Questcor Sees Revenue Ahead of Consensus

The pharmaceuticals company said paid prescriptions for its Acthar Gel to treat multiple sclerosis more than doubled. The company estimated it had first-quarter sale of $48.6 million, while analysts had expected $33.60 million. QCOR climbs 14 percent before the bell.


(Chart courtesy of tradeMONSTER)
Share this article with your friends


Invest Like a Monster - San Antonio: October 9-10

Premium Services

Education & Strategy

Real vs. Synthetic

We now know that there are two ways of creating a call position, a put position, and a stock position. We can simply use the actual real security or we can recreate it synthetically. We can create these positions in both long and short forms and this ability sets up an interesting scenario--an arbitrage!

View more education articles »